Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris

Circulation Journal

Volumn 74, Issue 3, 2010, Pages 589-591

  Kikuchi, Yoku ^a   Ito, Kenta ^a   Ito, Yoshitaka ^a   Shiroto, Takashi ^a   Tsuburaya, Ryuji ^a   Aizawa, Kentaro ^a   Hao, Kiyotaka ^a   Fukumoto, Yoshihiro ^a   Takahashi, Jun ^a   Takeda, Morihiko ^a   Nakayama, Masaharu ^a   Yasuda, Satoshi ^a   Kuriyama, Shinichi ^a   Tsuji, Ichiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angina pectoris; Angiogenesis; Myocardial ischemia; Shock wave

Indexed keywords

GLYCERYL TRINITRATE; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL LITHOTRIPSY; FEMALE; HEART FUNCTION; HUMAN; MALE; NON INVASIVE PROCEDURE; PATIENT SAFETY; THERAPY EFFECT; THORAX PAIN;

AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CHEST PAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHOTRIPSY; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 77649217983     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-1028     Document Type: Article

References (15)

1. Ma E, Iso H, Takahashi H, Yamagishi K, Tanigawa T. Age-periodcohort analysis of mortality due to ischemic heart disease in Japan, 1955 to 2000. Circ J 2008; 72: 966-972.
2. World Health Organization. Program Fact Sheet #310: 2004 Death Rates. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html (accessed 6 January, 2010).
3. Ito K, Fukumoto Y, Shimokawa H. Extracorporeal shock wave therapy as a new and non-invasive angiogenic therapy. Tohoku J Exp Med 2009; 219: 1-9.
4. Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 2004; 110: 3055-3061.
5. Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 2006; 17: 63-70.
6. Uwatoku T, Ito K, Abe K, Oi K, Hizume T, Sunagawa K, et al. Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. Coron Artery Dis 2007; 18: 397-404.
7. Oi K, Fukumoto Y, Ito K, Uwatoku T, Abe K, Hizume T, et al. Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. Tohoku J Exp Med 2008; 214: 151-158.
8. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105: 724-736.
9. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Therapeutic interventions for enhancing collateral development by administration of growth factors: Basic principles, early results and potential hazards. Cardiovasc Res 2001; 49: 532-542.
10. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005; 115: 572-583.
11. + stem cells for intractable angina: A phase I/IIa double-blind, randomized controlled trial. Circulation 2007; 115: 3165-3172.
12. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: A randomized controlled trial. JAMA 2009; 301: 1997-2004.
13. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219.
14. Aicher A, Heeschen C, Sasaki K, Urbich C, Zeiher AM, Dimmeler S. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: A new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006; 114: 2823-2830.
15. Yip HK, Chang LT, Sun CK, Youssef AA, Sheu JJ, Wang CJ. Shock wave therapy applied to rat bone marrow-derived mononuclear cells enhances formation of cells stained positive for CD31 and vascular endothelial growth factor. Circ J 2008; 72: 150-156.